Novo Nordisk A/S $NVO Shares Acquired by Hara Capital LLC

Hara Capital LLC increased its position in Novo Nordisk A/S (NYSE:NVO) by 50.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 69,954 shares of the company’s stock after buying an additional 23,537 shares during the quarter. Novo Nordisk A/S comprises about 2.0% of Hara Capital LLC’s investment portfolio, making the stock its 11th biggest position. Hara Capital LLC’s holdings in Novo Nordisk A/S were worth $3,559,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. True Wealth Design LLC raised its holdings in shares of Novo Nordisk A/S by 209.8% in the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after purchasing an additional 300 shares during the period. Guerra Advisors Inc purchased a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth about $25,000. Strengthening Families & Communities LLC purchased a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth about $30,000. Allianz SE increased its position in Novo Nordisk A/S by 70.0% during the 3rd quarter. Allianz SE now owns 578 shares of the company’s stock worth $32,000 after purchasing an additional 238 shares in the last quarter. Finally, Financial Life Planners acquired a new stake in Novo Nordisk A/S during the 3rd quarter worth approximately $33,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of NYSE:NVO opened at $36.71 on Wednesday. The business’s 50-day simple moving average is $44.90 and its 200 day simple moving average is $50.16. The company has a market cap of $163.90 billion, a P/E ratio of 10.58, a PEG ratio of 8.35 and a beta of 0.73. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. Novo Nordisk A/S has a one year low of $35.12 and a one year high of $81.44.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. The firm had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. On average, sell-side analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The company also recently announced a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be paid a $1.2751 dividend. The ex-dividend date is Monday, March 30th. This represents a dividend yield of 723.0%. Novo Nordisk A/S’s dividend payout ratio is 52.74%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on NVO. Jefferies Financial Group raised shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research report on Thursday, February 12th. CICC Research assumed coverage on shares of Novo Nordisk A/S in a research report on Friday, January 9th. They issued an “outperform” rating and a $73.50 price objective for the company. The Goldman Sachs Group reissued a “neutral” rating and issued a $41.00 target price (down from $63.00) on shares of Novo Nordisk A/S in a research note on Monday, March 2nd. Citigroup started coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 27th. They set a “neutral” rating on the stock. Finally, Sanford C. Bernstein began coverage on shares of Novo Nordisk A/S in a research report on Wednesday, March 18th. They set an “outperform” rating and a $175.00 price target for the company. Four equities research analysts have rated the stock with a Buy rating, nineteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $65.56.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: UK cost?effectiveness watchdog recommended use of Wegovy to reduce major heart risks in obese/overweight adults — the first GLP?1 endorsed for this indication, which could broaden prescribing and boost long?term demand. British drug-cost watchdog recommends use of Novo’s Wegovy to lower heart risks
• Positive Sentiment: Launched discounted multi?month Wegovy subscriptions for U.S. self?pay patients (up to ~30% off standard monthly rate) to improve access and predictable pricing — a defensive commercial move to regain share vs. Eli Lilly and to stabilize cash?pay volumes. Novo Nordisk to launch discounted Wegovy subscriptions for self-pay patients in US
• Positive Sentiment: Company is executing a share repurchase programme (part of a previously announced DKK 15bn plan), which supports EPS and signals management confidence in the business. Novo Nordisk A/S – share repurchase programme
• Positive Sentiment: Completed a key China study for a new obesity/diabetes candidate — clinical progress in large markets can materially increase future upside. Novo Nordisk Advances New Obesity and Diabetes Drug With Key China Study Completion
• Positive Sentiment: Expanded distribution/affordability through partnerships (Hims telehealth GLP?1 offering; Weight Watchers preferred pricing via NovoCare) — these broaden channels for self?pay and insured patients. Hims GLP 1 Deal With Novo Nordisk Reshapes Growth And Valuation Story Weight Watchers Announces Best-in-Market Self-Pay Wegovy Pricing
• Neutral Sentiment: Company and rival Lilly are using AI across drug development to accelerate pipelines — a structural positive over the long term but not an immediate earnings driver. Lilly and Novo Show How AI Is Rewiring Big Pharma
• Negative Sentiment: Further deep price cuts in India for Ozempic and Wegovy (up to ~36–48%) to fend off local generics — helps retain volumes but pressures margins in a large market. Novo Nordisk further slashes prices of Ozempic, Wegovy in India
• Negative Sentiment: Planned layoffs at the Bloomington, Indiana manufacturing site (about 400 jobs) highlight cost?cutting and operational reshaping; may be viewed negatively by some investors despite potential near?term margin benefits. Novo Nordisk to lay off 400 Bloomington employees

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.